Juvelook Wins 'Best Injectable of Skin Revitalization' at 2025 AMWC, Gaining Global Recognition

Juvelook Wins 'Best Injectable of Skin Revitalization' at 2025 AMWC, Gaining Global Recognition

VAIM (formerly VAIM Global), a leading medical aesthetics company, has proudly announced that its flagship product, Juvelook, has been awarded the prestigious title of 'Best Injectable of Skin Revitalization' at the 23rd Aesthetic & Anti-Aging Medicine World Congress (AMWC) held in Monaco from March 27 to 29, 2025.

AMWC is one of the most renowned global conferences in the field of aesthetics and anti-aging medicine. More than 15,000 industry professionals, including dermatologists and medical practitioners, from over 200 countries, along with more than 350 participating companies participated in this congress. As a leading hub for innovation, AMWC drives industry trends and advancements.

Juvelook’s win in the Best Injectable for Skin Revitalization at the 12th AMWC Aesthetic Medicine Awards highlights its unique technology and exceptional efficacy, further cementing VAIM’s reputation as a global leader in medical aesthetics.

During AMWC, VAIM had a two-day symposium showcasing the latest research and clinical applications of Juvelook and Lenisna.

On the first day, Dr. Tapan delivered an insightful symposium on Juvelook’s mechanism of collagen regeneration through adipose-derived mesenchymal stem cells. Following this, Dr. Olga conducted a live demonstration, sharing her unique technique for utilizing Juvelook in under-eye treatments. On the second day, Dr. Park Je-Young led an in-depth lecture on the latest innovations in volumizing treatments using Lenisna. He also shared this experience of Lenisna injection skills through live demonstrations during symposium.

A VAIM representative remarked, "This award confirms that Juvelook is gaining significant attention in the global market. Through our symposium and booth activities, we were able to share Juvelook's outstanding technological capabilities and successful clinical cases—making it a meaningful opportunity to introduce the brand to global doctors and industry professionals."

VAIM remains committed to continuous research and global market expansion, striving to deliver innovative medical aesthetic solutions to practitioners and patients worldwide.

Introduction of VAIM
Founded in 2014, VAIM is a global medical aesthetics company that develops human tissue regeneration products and improved pharmaceuticals by utilizing its accumulated technology and know-how in biocompatible and biodegradable polymers. It has developed and patented a PDLLA-based manufacturing technology that reduces the risk of nodule formation compared to other ingredient structures, and in 2019, its subsidiary, VAIM Global, entered the skin booster market with JUVELOOK, which utilizes this technology. JUVELOOK is a collagen booster that induces the production of ECM (collagen, elastin) to provide direct remodeling effects on the skin such as elasticity and wrinkle improvement, and is divided into JUVELOOK and LENISNA depending on the purpose. After quickly proving its safety and effectiveness since its launch, VAIM Global currently has product export contracts with 72 countries.